Obesity - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 514 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Obesity - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Obesity - Pipeline Review, H1 2015', provides an overview of the Obesity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Obesity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Obesity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
Introduction 8
Obesity Overview 9
Therapeutics Development 10
Obesity - Therapeutics under Development by Companies 12
Obesity - Therapeutics under Investigation by Universities/Institutes 21
Obesity - Pipeline Products Glance 25
Obesity - Products under Development by Companies 29
Obesity - Products under Investigation by Universities/Institutes 41
Obesity - Companies Involved in Therapeutics Development 45
Obesity - Therapeutics Assessment 139
Drug Profiles 158
Obesity - Recent Pipeline Updates 407
Obesity - Dormant Projects 458
Obesity - Discontinued Products 474
Obesity - Product Development Milestones 481
Appendix 490

List of Tables
Number of Products under Development for Obesity, H1 2015 33
Number of Products under Development for Obesity - Comparative Analysis, H1 2015 34
Number of Products under Development by Companies, H1 2015 36
Number of Products under Development by Companies, H1 2015 (Contd..1) 37
Number of Products under Development by Companies, H1 2015 (Contd..2) 38
Number of Products under Development by Companies, H1 2015 (Contd..3) 39
Number of Products under Development by Companies, H1 2015 (Contd..4) 40
Number of Products under Development by Companies, H1 2015 (Contd..5) 41
Number of Products under Development by Companies, H1 2015 (Contd..6) 42
Number of Products under Development by Companies, H1 2015 (Contd..7) 43
Number of Products under Investigation by Universities/Institutes, H1 2015 45
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 46
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 47
Comparative Analysis by Late Stage Development, H1 2015 48
Comparative Analysis by Clinical Stage Development, H1 2015 49
Comparative Analysis by Early Stage Development, H1 2015 50
Comparative Analysis by Unknown Stage Development, H1 2015 51
Products under Development by Companies, H1 2015 52
Products under Development by Companies, H1 2015 (Contd..1) 53
Products under Development by Companies, H1 2015 (Contd..2) 54
Products under Development by Companies, H1 2015 (Contd..3) 55
Products under Development by Companies, H1 2015 (Contd..4) 56
Products under Development by Companies, H1 2015 (Contd..5) 57
Products under Development by Companies, H1 2015 (Contd..6) 58
Products under Development by Companies, H1 2015 (Contd..7) 59
Products under Development by Companies, H1 2015 (Contd..8) 60
Products under Development by Companies, H1 2015 (Contd..9) 61
Products under Development by Companies, H1 2015 (Contd..10) 62
Products under Development by Companies, H1 2015 (Contd..11) 63
Products under Investigation by Universities/Institutes, H1 2015 64
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 65
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 66
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 67
Obesity - Pipeline by Advinus Therapeutics Ltd., H1 2015 68
Obesity - Pipeline by Aegis Therapeutics, LLC, H1 2015 69
Obesity - Pipeline by Aileron Therapeutics, Inc., H1 2015 70
Obesity - Pipeline by Akron Molecules AG, H1 2015 71
Obesity - Pipeline by Alize Pharma SAS, H1 2015 72
Obesity - Pipeline by Ambrx, Inc., H1 2015 73
Obesity - Pipeline by Amgen Inc., H1 2015 74
Obesity - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 75
Obesity - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 76
Obesity - Pipeline by Arrowhead Research Corporation, H1 2015 77
Obesity - Pipeline by AstraZeneca PLC, H1 2015 78
Obesity - Pipeline by AtheroNova Inc., H1 2015 79
Obesity - Pipeline by Athersys, Inc., H1 2015 80
Obesity - Pipeline by Avaxia Biologics, Inc., H1 2015 81
Obesity - Pipeline by BioRestorative Therapies, Inc., H1 2015 82
Obesity - Pipeline by Braasch Biotech LLC, H1 2015 83
Obesity - Pipeline by Bridge Bioresearch Plc, H1 2015 84
Obesity - Pipeline by Bristol-Myers Squibb Company, H1 2015 85
Obesity - Pipeline by Calzada Limited, H1 2015 86
Obesity - Pipeline by Carmot Therapeutics, Inc., H1 2015 87
Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 88
Obesity - Pipeline by Chronos Therapeutics Limited, H1 2015 89
Obesity - Pipeline by CrystalGenomics, Inc., H1 2015 90
Obesity - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 91
Obesity - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 92
Obesity - Pipeline by Diabetica Limited, H1 2015 93
Obesity - Pipeline by Digna Biotech, S.L., H1 2015 94
Obesity - Pipeline by DiscoveryBiomed, Inc., H1 2015 95
Obesity - Pipeline by Eisai Co., Ltd., H1 2015 96
Obesity - Pipeline by Eli Lilly and Company, H1 2015 97
Obesity - Pipeline by Esperion Therapeutics, Inc., H1 2015 98
Obesity - Pipeline by Euroscreen S.A., H1 2015 99
Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 100
Obesity - Pipeline by Galapagos NV, H1 2015 101
Obesity - Pipeline by Galenea Corp., H1 2015 102
Obesity - Pipeline by Genfit SA, H1 2015 103
Obesity - Pipeline by GlaxoSmithKline plc, H1 2015 104
Obesity - Pipeline by GTx, Inc., H1 2015 105
Obesity - Pipeline by Handok Inc., H1 2015 106
Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 107
Obesity - Pipeline by Helsinn Healthcare S.A., H1 2015 108
Obesity - Pipeline by High Point Pharmaceuticals, LLC, H1 2015 109
Obesity - Pipeline by Insusense Therapeutics ApS, H1 2015 110
Obesity - Pipeline by Intarcia Therapeutics, Inc., H1 2015 111
Obesity - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 112
Obesity - Pipeline by Jenrin Discovery, Inc., H1 2015 113
Obesity - Pipeline by Johnson & Johnson, H1 2015 114
Obesity - Pipeline by Kainos Medicine, Inc., H1 2015 115
Obesity - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 116
Obesity - Pipeline by Lead Discovery Center GmbH, H1 2015 117
Obesity - Pipeline by LG Life Sciences, Ltd., H1 2015 118
Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 119
Obesity - Pipeline by Molecular Design International, Inc., H1 2015 120
Obesity - Pipeline by Neothetics, Inc. , H1 2015 121
Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H1 2015 122
Obesity - Pipeline by nLife Therapeutics, S.L., H1 2015 123
Obesity - Pipeline by Nordic Bioscience a/s, H1 2015 124
Obesity - Pipeline by Novo Nordisk A/S, H1 2015 125
Obesity - Pipeline by ObeTherapy Biotechnology, H1 2015 126
Obesity - Pipeline by Omeros Corporation, H1 2015 127
Obesity - Pipeline by OPKO Health, Inc., H1 2015 128
Obesity - Pipeline by Orbis Biosciences, Inc., H1 2015 129
Obesity - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2015 130
Obesity - Pipeline by Orexigen Therapeutics, Inc., H1 2015 131
Obesity - Pipeline by P2D Bioscience, H1 2015 132
Obesity - Pipeline by Pfizer Inc., H1 2015 133
Obesity - Pipeline by PharmaIN Corporation, H1 2015 134
Obesity - Pipeline by Piramal Enterprises Limited, H1 2015 135
Obesity - Pipeline by Plexxikon Inc., H1 2015 136
Obesity - Pipeline by Prometheon Pharma, LLC, H1 2015 137
Obesity - Pipeline by Regulus Therapeutics Inc., H1 2015 138
Obesity - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 139
Obesity - Pipeline by Rhythm Pharmaceuticals, H1 2015 140
Obesity - Pipeline by Saniona AB, H1 2015 141
Obesity - Pipeline by Sanofi, H1 2015 142
Obesity - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2015 143
Obesity - Pipeline by Shionogi & Co., Ltd., H1 2015 144
Obesity - Pipeline by Sirona Biochem Corp, H1 2015 145
Obesity - Pipeline by Sorrento Therapeutics, Inc., H1 2015 146
Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 147
Obesity - Pipeline by Suven Life Sciences Ltd., H1 2015 148
Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 149
Obesity - Pipeline by Transition Therapeutics Inc., H1 2015 150
Obesity - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 151
Obesity - Pipeline by Versartis, Inc., H1 2015 152
Obesity - Pipeline by Verva Pharmaceuticals Limited, H1 2015 153
Obesity - Pipeline by Vicore Pharma AB, H1 2015 154
Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 155
Obesity - Pipeline by X-BODY BioSciences, Inc., H1 2015 156
Obesity - Pipeline by Xenetic Biosciences plc, H1 2015 157
Obesity - Pipeline by XL-protein GmbH, H1 2015 158
Obesity - Pipeline by Zafgen Inc., H1 2015 159
Obesity - Pipeline by Zealand Pharma A/S, H1 2015 160
Obesity - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 161
Assessment by Monotherapy Products, H1 2015 162
Assessment by Combination Products, H1 2015 163
Number of Products by Stage and Target, H1 2015 165
Number of Products by Stage and Mechanism of Action, H1 2015 172
Number of Products by Stage and Route of Administration, H1 2015 178
Number of Products by Stage and Molecule Type, H1 2015 180
Obesity Therapeutics - Recent Pipeline Updates, H1 2015 430
Obesity - Dormant Projects, H1 2015 481
Obesity - Dormant Projects (Contd..1), H1 2015 482
Obesity - Dormant Projects (Contd..2), H1 2015 483
Obesity - Dormant Projects (Contd..3), H1 2015 484
Obesity - Dormant Projects (Contd..4), H1 2015 485
Obesity - Dormant Projects (Contd..5), H1 2015 486
Obesity - Dormant Projects (Contd..6), H1 2015 487
Obesity - Dormant Projects (Contd..7), H1 2015 488
Obesity - Dormant Projects (Contd..8), H1 2015 489
Obesity - Dormant Projects (Contd..9), H1 2015 490
Obesity - Dormant Projects (Contd..10), H1 2015 491
Obesity - Dormant Projects (Contd..11), H1 2015 492
Obesity - Dormant Projects (Contd..12), H1 2015 493
Obesity - Dormant Projects (Contd..13), H1 2015 494
Obesity - Dormant Projects (Contd..14), H1 2015 495
Obesity - Dormant Projects (Contd..15), H1 2015 496
Obesity - Discontinued Products, H1 2015 497
Obesity - Discontinued Products (Contd..1), H1 2015 498
Obesity - Discontinued Products (Contd..2), H1 2015 499
Obesity - Discontinued Products (Contd..3), H1 2015 500
Obesity - Discontinued Products (Contd..4), H1 2015 501
Obesity - Discontinued Products (Contd..5), H1 2015 502
Obesity - Discontinued Products (Contd..6), H1 2015 503